Catalogue Number: DIA-W09-DIA
| Manufacturer: | Dianova |
| Preservative: | 0.05% Sodium azide |
| Physical state: | Lyophilized |
| Type: | Monoclonal Primary Antibody - Unconjugated |
| Alias: | IDH1;Isocitrate dehydrogenase [NADP] (cytoplasmic);PICD;IDP;Oxalosuccinate decarboxylase;NADP(+)-specific ICDH;Cytosolic NADP-isocitrate dehydrogenase;Isocitrate Dehydrogenase 1, Soluble |
| Shipping Condition: | RT |
| Storage Condition: | 2-8°C |
| Unit(s): | 0.5 ml |
| Host name: | Rat |
| Clone: | W09 |
| Isotype: | IgG2a |
| Immunogen: | Peptide sequence 4-120 of human IDH1 |
| Application: | ICC, IHC-P, WB, IHC |
Description: Isocitrate dehydrogenase (IDH) is an important enzyme in the citric acid cycle and catalyzes the oxidative decarboxylation of isocitrate to alpha-ketoglutarate and CO2 while converting NAD+ to NADH. Heterozygous point mutations of IDH1 codon 132 are frequent in World Health Organization (WHO) grade II and III gliomas. IDH1 R132H mutations occur in approximately 70% of astrocytomas and oligodendroglial tumors. Mouse antibody clone H09 (product number #DIA-H09) reacts specifically with the isocitrate dehydrogenase 1 (IDH1) R132H point mutation in tissue sec-tions from formalin-fixed brain tumor specimens. Therefore this antibody is highly useful for tumor classification. Rat antibody clone W09 detects both wild type (wt) and point mutated IDH1 in glioblastoma (anti-pan-IDH1) and serves as control for the IDH1 point mutation specific mouse antibody clone H09. Moreover, Tan et al. (Mol Cell Proteomics, 2011) have identified IDH1 as a potential diagnostic and prognostic biomarker for Non-small-cell Lung Cancer (NSCLC). These findings suggest that anti-IDH1wt antibody could be used as a histochemical biomarker for prognosis prediction of NSCLC. Human IDH1, wild type & point mutation
IDH1
Protein A/G Purified
O75874
3417
Monoclonal